China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Up 115.5% in January

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 7,347,822 shares, an increase of 115.5% from the January 15th total of 3,408,880 shares. Based on an average daily trading volume, of 35,892,593 shares, the days-to-cover ratio is presently 0.2 days. Currently, 794.4% of the shares of the stock are short sold. Currently, 794.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 35,892,593 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC increased its holdings in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) by 107.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,983 shares of the company’s stock after purchasing an additional 15,013 shares during the period. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 at the end of the most recent quarter. 5.02% of the stock is currently owned by institutional investors.

China SXT Pharmaceuticals Trading Up 5.6%

NASDAQ SXTC opened at $2.63 on Friday. The business’s 50-day moving average price is $119.84 and its two-hundred day moving average price is $190.83. China SXT Pharmaceuticals has a 12 month low of $2.34 and a 12 month high of $1,176.00.

China SXT Pharmaceuticals (NASDAQ:SXTC) last posted its quarterly earnings data on Wednesday, December 31st. The company reported ($4.50) EPS for the quarter. The company had revenue of $0.31 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a research report on Saturday, February 7th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.